Cost Per Responder Analysis of Guselkumab Versus Etanercept Using Efficacy Results from Pivotal Clinical Trials in Patients with Moderate to Severe Plaque Psoriasis
May 1, 2018, 00:00
10.1016/j.jval.2018.04.1635
https://www.valueinhealthjournal.com/article/S1098-3015(18)31941-7/fulltext
Title :
Cost Per Responder Analysis of Guselkumab Versus Etanercept Using Efficacy Results from Pivotal Clinical Trials in Patients with Moderate to Severe Plaque Psoriasis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)31941-7&doi=10.1016/j.jval.2018.04.1635
First page :
Section Title :
Open access? :
No
Section Order :
861